Microsomal acyl glucuronidation: enzyme-kinetic studies with labile glucuronides
- PMID: 8488171
- DOI: 10.1159/000139054
Microsomal acyl glucuronidation: enzyme-kinetic studies with labile glucuronides
Abstract
Because of the labile nature of acyl glucuronides under physiologic conditions, metabolic rates of formation calculated using traditional methods may be confounded by concomitant rates of degradation. True metabolic formation rates may be approximated by stabilization of the metabolic product or by purifying the metabolite and calculating its degradation rate under similar conditions to that utilized in the formation experiments. This latter degradation rate is used to correct the apparent formation parameter in the absence of inhibitors. The advantages and limitations of each approach are reviewed employing studies to characterize rates of acyl glucuronidation for nonsteroidal antiinflammatory drugs.
Similar articles
-
Contribution of the human kidney to the metabolic clearance of drugs.Ann Pharmacother. 1992 Nov;26(11):1421-8. doi: 10.1177/106002809202601116. Ann Pharmacother. 1992. PMID: 1477449 Review.
-
Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes.Br J Pharmacol. 2001 Mar;132(5):1027-34. doi: 10.1038/sj.bjp.0703898. Br J Pharmacol. 2001. PMID: 11226133 Free PMC article.
-
Effect of selective phase II enzyme inducers on glucuronidation of benoxaprofen in rats.Drug Metab Dispos. 1999 Dec;27(12):1423-8. Drug Metab Dispos. 1999. PMID: 10570023
-
N-Glucuronidation of the antiepileptic drug retigabine: results from studies with human volunteers, heterologously expressed human UGTs, human liver, kidney, and liver microsomal membranes of Crigler-Najjar type II.Metabolism. 2006 Jun;55(6):711-21. doi: 10.1016/j.metabol.2006.01.006. Metabolism. 2006. PMID: 16713428 Clinical Trial.
-
Species differences in N-glucuronidation.Drug Metab Dispos. 1998 Sep;26(9):838-47. Drug Metab Dispos. 1998. PMID: 9733661 Review.
Cited by
-
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.Clin Pharmacokinet. 1992 Oct;23(4):292-310. doi: 10.2165/00003088-199223040-00005. Clin Pharmacokinet. 1992. PMID: 1395362 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources